# Impact of PCSK9 Inhibition on Clinical Outcome in Patients During the Inflammatory Stage of the COVID-19

> **NCT04941105** · PHASE3 · COMPLETED · sponsor: **Collegium Medicum w Bydgoszczy** · enrollment: 60 (actual)

## Conditions studied

- Sars-CoV-2 Infection

## Interventions

- **DRUG:** Evolocumab
- **DRUG:** Saline solution

## Key facts

- **NCT ID:** NCT04941105
- **Lead sponsor:** Collegium Medicum w Bydgoszczy
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-01
- **Primary completion:** 2022-05-17
- **Final completion:** 2022-05-17
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2023-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04941105

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04941105, "Impact of PCSK9 Inhibition on Clinical Outcome in Patients During the Inflammatory Stage of the COVID-19". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04941105. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*